Home › All Companies › ALMS › Annual Report

ALUMIS INC. (ALMS) — Annual Report

AI-Powered SEC Filing Analysis

← All ALMS filings
Latest Annual Report Filed: 2026-03-19

Key Insights

  • Alumis Inc. has recently completed an IPO and private placement, raising significant additional capital to fund its operations and growth initiatives.
  • The company has entered into a collaborative arrangement with Kaken Pharmaceutical Co. Ltd. for the development and commercialization of its lead product candidate, Esk001, which could provide a significant revenue stream and further strengthen its financial position.
  • The company has made investments in property, plant, and equipment, including software development, leasehold improvements, and laboratory equipment, to support its ongoing research and development activities.
Sentiment: Positive Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-19. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for ALUMIS INC.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.